GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Pre-Tax Income

Nyrada (ASX:NYR) Pre-Tax Income : A$-4.98 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Nyrada Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Nyrada's pretax income for the six months ended in Dec. 2023 was A$0.14 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was A$-4.98 Mil. Nyrada's pretax margin was %.


Nyrada Pre-Tax Income Historical Data

The historical data trend for Nyrada's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyrada Pre-Tax Income Chart

Nyrada Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Pre-Tax Income
- -5.77 -3.54 -3.96 -7.78

Nyrada Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Pre-Tax Income Get a 7-Day Free Trial -2.80 -1.16 -2.67 -5.12 0.14

Competitive Comparison of Nyrada's Pre-Tax Income

For the Biotechnology subindustry, Nyrada's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nyrada's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nyrada's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Nyrada's Pre-Tax Income falls into.



Nyrada Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Nyrada's Pretax Income for the fiscal year that ended in Jun. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-9.36+1.43+0+0.149+-0.0010000000000003
=-7.78

Nyrada's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-2.321+2.457+0+0+3.3306690738755E-16
=0.14

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-4.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nyrada  (ASX:NYR) Pre-Tax Income Explanation

Nyrada's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pretax Income/Revenue
=0.136/0
=%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nyrada Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Nyrada's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Nyrada (ASX:NYR) Business Description

Traded in Other Exchanges
N/A
Address
828 Pacific Highway, Suite 2, Level 3, Gordon, NSW, AUS, 2072
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

Nyrada (ASX:NYR) Headlines

No Headlines